Neuronal TIMP-1 release accompanies astrocytic MMP-9 secretion and enhances astrocyte proliferation induced by β-amyloid 25-35 fragment

Journal of Neuroscience Research

Volumn 87, Issue 9, 2009, Pages 2115-2125

  Hernández Guillamon, Mar ^a   Delgado, Pilar ^a   Ortega, Laura ^a   Pares, Mireia ^a   Rosell, Anna ^a   García Bonilla, Lidia ^a   Fernández Cadenas, Israel ^a   Borrell Pagès, Maria ^a   Boada, Mercè ^a,b   Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b Institut Catala de Neurociencies Aplicades   (Spain)

Author keywords

Amyloid 25 35 fragment; Astrocyte proliferation; MMP 9; Neuronal toxicity; TIMP 1

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME RELEASE; GLIA CELL; GLIOSIS; MACROGLIA; NERVE CELL; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN SECRETION; RAT; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ASTROCYTES; CELL COMMUNICATION; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG SYNERGISM; ENCEPHALITIS; GLIOSIS; MATRIX METALLOPROTEINASE 9; NEURONS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; SENILE PLAQUES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 65849506917     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22034     Document Type: Article

References (45)

1. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. 1997. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 5:406-415.
2. Araujo DM, Cotman CW. 1992. Beta-amyloid stimulates glial cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res 569:141-145.
3. Asahina M, Yoshiyama Y, Hattori T. 2001. Expression of matrix metalloproteinase- 9 and urokinase-type plasminogen activator in Alzheimer's disease brain. Clin Neuropathol 20:60-63.
4. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA. 1996. Matrix metalloproteinase- 9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16:7910-7919.
5. Baig S, Kehoe PG, Love S. 2008. MMP-2, -3 and -9 levels and activity are not related to Abeta load in the frontal cortex in Alzheimer's disease. Neuropathol Appl Neurobiol 34:205-215.
6. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 1477:267-283.
7. Clark AW, Krekoski CA, Bou SS, Chapman KR, Edwards DR. 1997. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 238:53-56.
8. Davidsen ML, Würtz SØ, Rømer MU, Sørensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brünner N, Lademann U. 2006. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 95:1114-1120.
9. Deb S, Gottschall PE. 1996. Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66:1641-1647.
10. Deb S, Wenjun Zhang J, Gottschall PE. 2003. Beta-amyloid induces the production of active, matrix-degrading proteases in cultured rat astrocytes. Brain Res 970:205-213.
11. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB. 2006. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281:30471-30478.
12. Estus S, Tucker HM, van Rooyen C, Wright S, Brigham EF, Wogulis M, Rydel RE. 1997. Aggregated amyloid-beta protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction. J Neurosci 17:7736-7745.
13. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S. 2003. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100:4162-4167.
14. Goldberg MP, Choi DW. 1993. Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. J Neurosci 13:3510-3524.
15. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA. 2002. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297:1186-1190.
16. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA. 2005. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 25:6401-6408.
17. Guo S, Wang S, Kim WJ, Lee SR, Frosch MP, Bacskai BJ, Greenberg SM, Lo EH. 2006. Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes. Brain Res 1111:222-226.
18. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
19. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. 1992. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298:29-32.
20. Howell S, Nalbantoglu J, Crine P. 1995. Neutral endopeptidase can hydrolyze beta-amyloid (1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 6:647-652.
21. Hu J, Van Eldik LJ. 1999. Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation. Brain Res 842:46-54.
22. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC. 2000. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6:43-50.
23. Jourquin J, Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S. 2003. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate. Eur J Neurosci 18:1507-1517.
24. Jourquin J, Tremblay E, Bernard A, Charton G, Chaillan FA, Marchetti E, Roman FS, Soloway PD, Dive V, Yiotakis A, Khrestchatisky M, Rivera S. 2005. Tissue inhibitor of metalloproteinases-1 (TIMP-1) modulates neuronal death, axonal plasticity, and learning and memory. Eur J Neurosci 22:2569-2578.
25. Jung SS, Zhang W, Van Nostrand WE. 2003. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 85:1208-1215.
26. Kurochkin IV, Goto S. 1994. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345:33-37.
27. Lee JM, Yin K, Hsin I, Chen S, Fryer JD, Holtzman DM, Hsu CY, Xu J. 2005. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathyrelated hemorrhage. J Neurol Sci 229/230:249-254.
28. Lee SJ, Yoo HJ, Bae YS, Kim HJ, Lee ST. 2003. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin sensitive G protein and c-Src. Biochem Biophys Res Commun 312:1196-1201.
29. Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, Beal MF. 2003a. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 207:71-76.
30. Lorenzl S, Albers DS, Relkin N, Ngyuen T, Hilgenberg SL, Chirichigno J, Cudkowicz ME, Beal MF. 2003b. Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease. Neurochem Int 43:191-196.
31. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L. 2006. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51:703-714.
32. Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, Rogers JH. 2002. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. Brain Res Mol Brain Res 100:103-117.
33. Ogier C, Creidy R, Boucraut J, Soloway PD, Khrestchatisky M, Rivera S. 2005. Astrocyte reactivity to Fas activation is attenuated in TIMP-1 deficient mice, an in vitro study. BMC Neurosci 6:68.
34. Peress N, Perillo E, Zucker S. 1995. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J Neuropathol Exp Neurol 54:16-22.
35. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. 1995. Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J Neurochem 64:253-265.
36. Rivera S, Tremblay E, Timsit S, Canals O, Ben-Ari Y, Khrestchatisky M. 1997. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J Neurosci 17:4223-4235.
37. Rivera S, Ogier C, Jourquin J, Timsit S, Szklarczyk AW, Miller K, Gearing AJ, Kaczmarek L, Khrestchatisky M. 2002. Gelatinase B and TIMP-1 are regulated in a cell- and time-dependent manner in association with neuronal death and glial reactivity after global forebrain ischemia. Eur J Neurosci 15:19-32.
38. Roher AE, Kasunic TC, Woods AS, Cotter RJ, Ball MJ, Fridman R. 1994. Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun 205: 1755-1761.
39. Rosell A, Ortega-Aznar A, Alvarez-Sabin J, Fernandez-Cadenas I, Ribo M, Molina CA, Lo EH, Montaner J. 2006. Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37:1399-1406.
40. Selkoe DJ. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399:A23-A31.
41. Tan HK, Heywood D, Ralph GS, Bienemann A, Baker AH, Uney JB. 2003. Tissue inhibitor of metalloproteinase 1 inhibits excitotoxic cell death in neurons. Mol Cell Neurosci 22:98-106.
42. Tokay T, Masmoudi O, Gandolfo P, Leprince J, Pelletier G, Vaudry H, Tonon MC. 2005. Beta-amyloid peptides stimulate endozepine biosynthesis in cultured rat astrocytes. J Neurochem 94:607-616.
43. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM. 2006. Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281:24566-24574.
44. Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM. 2006. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J Neurosci 26:10939-10948.
45. Yong VW, Power C, Forsyth P, Edwards DR. 2001. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2:502-511.